EQ Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 30.30%

Insider Buying (Last 12 Months): $0.00

Insider Selling (Last 12 Months): $86,432.60

Equillium Insider Trading History Chart

Equillium Share Price & Price History

^$0.39

▼ -0.0131 (-3.23%)

As of 03/31/2025 05:00 PM ET

Days: 30 | 90 | 365

Equillium Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
1/23/2025	Jason A Keyes	CFO	Sell	10,000	$0.65	$6,500.00	37,720
11/14/2024	Jason A Keyes	CFO	Sell	10,000	$0.70	$7,000.00	47,720
10/28/2024	Christine Zedelmayer	COO	Sell	15,000	$1.25	$18,750.00	135,246
10/28/2024	Penny Tom	Insider	Sell	2,835	$1.25	$3,543.75	6,533
10/25/2024	Penny Tom	Insider	Sell	683	$1.25	$853.75	9,368
9/26/2024	Jason A Keyes	CFO	Sell	10,000	$0.81	$8,100.00	57,720
9/16/2024	Penny Tom	Insider	Sell	38,806	$0.85	$32,985.10	10,051
7/16/2024	Jason A Keyes	CFO	Sell	10,000	$0.87	$8,700.00	67,720
8/29/2022	Jason A Keyes	CFO	Sell	7,000	$2.83	$19,810.00	77,720
6/6/2022	Jason A Keyes	CFO	Sell	5,000	$2.52	$12,600.00	84,720
4/4/2022	Jason A Keyes	CFO	Sell	8,000	$3.18	$25,440.00	23,296

See Full Table

SEC Filings (Institutional Ownership Changes) for Equillium (NASDAQ:EQ)

27.05% of Equillium stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

Equillium Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
2/13/2025	Renaissance Technologies LLC	261,400	$0.20M	0.0%	-18.6%	0.738%
2/12/2025	Takeda Pharmaceutical Co. Ltd.	1,824,977	$1.37M	5.2%	N/A	5.151%
2/11/2025	DCF Advisers LLC	62,947	$47K	0.0%	+91.0%	0.178%
8/9/2024	Renaissance Technologies LLC	300,400	$0.21M	0.0%	+43.6%	0.852%
5/10/2024	Acadian Asset Management LLC	108,691	$0.25M	0.0%	N/A	0.308%
2/12/2024	Decheng Capital LLC	4,447,308	$3.22M	0.9%	N/A	12.663%
8/9/2023	DCF Advisers LLC	111,623	$84K	0.0%	-28.9%	0.324%
5/2/2023	Victory Capital Management Inc.	345,861	$0.25M	0.0%	-89.2%	1.005%
2/14/2023	True North Advisors LLC	265,370	$0.27M	0.1%	+50.5%	0.771%
2/13/2023	Callan Capital LLC	103,688	$0.11M	0.0%	N/A	0.301%
2/9/2023	Victory Capital Management Inc.	3,198,745	$3.52M	0.0%	-12.4%	9.296%
1/24/2023	Capital CS Group LLC	24,000	$25K	0.0%	N/A	0.070%
11/7/2022	Virtu Financial LLC	24,141	$54K	0.0%	N/A	0.070%
11/2/2022	Victory Capital Management Inc.	3,651,084	$8.11M	0.0%	+2.1%	10.651%
8/11/2022	DCF Advisers LLC	114,027	$0.23M	0.1%	-31.2%	0.333%
8/1/2022	Victory Capital Management Inc.	3,577,211	$7.30M	0.0%	-0.6%	10.436%
5/16/2022	Cota Capital Management LLC	562,278	$1.77M	0.4%	N/A	1.640%
5/10/2022	Decheng Capital Management III Cayman LLC	4,447,308	$14.01M	4.3%	N/A	12.975%
5/4/2022	Victory Capital Management Inc.	3,597,799	$11.33M	0.0%	+8.2%	10.495%
2/15/2022	Samsara BioCapital LLC	615,541	$2.32M	0.5%	-16.6%	2.094%
2/7/2022	Victory Capital Management Inc.	3,325,050	$12.47M	0.0%	+4.9%	11.313%
11/16/2021	Two Sigma Securities LLC	83,948	$0.57M	0.0%	N/A	0.286%
11/12/2021	Geode Capital Management LLC	154,185	$1.05M	0.0%	+2.4%	0.525%
11/2/2021	Victory Capital Management Inc.	3,170,199	$21.62M	0.0%	+9.4%	10.789%
8/17/2021	Samsara BioCapital LLC	738,176	$4.35M	0.5%	-3.4%	2.512%
8/17/2021	Bridgeway Capital Management LLC	141,200	$0.83M	0.0%	+38.4%	0.481%
8/16/2021	State Street Corp	30,756	$0.18M	0.0%	N/A	0.105%
8/16/2021	Goldman Sachs Group Inc.	218,162	$1.29M	0.0%	N/A	0.742%
8/13/2021	DCF Advisers LLC	77,538	$0.46M	0.2%	N/A	0.267%
8/13/2021	Geode Capital Management LLC	150,582	$0.89M	0.0%	+16.7%	0.519%
8/13/2021	Vanguard Group Inc.	840,545	$4.95M	0.0%	+31.4%	2.894%
8/11/2021	Deutsche Bank AG	356,461	$2.10M	0.0%	+1.8%	1.227%
8/3/2021	Victory Capital Management Inc.	2,896,875	$17.06M	0.0%	+1.0%	9.975%
5/21/2021	Citadel Advisors LLC	21,366	$0.15M	0.0%	N/A	0.074%
5/18/2021	Millennium Management LLC	63,012	$0.45M	0.0%	+413.3%	0.217%
5/18/2021	Citadel Advisors LLC	21,366	$0.15M	0.0%	N/A	0.074%
5/18/2021	Samsara BioCapital LLC	764,403	$5.47M	1.0%	-28.8%	2.632%
5/17/2021	Sphera Funds Management LTD.	254,184	$1.82M	0.1%	N/A	0.875%
5/12/2021	Northern Trust Corp	34,055	$0.24M	0.0%	+42.9%	0.117%
5/12/2021	Geode Capital Management LLC	129,072	$0.92M	0.0%	+99.0%	0.444%
5/7/2021	BlackRock Inc.	32,423	$0.23M	0.0%	-53.1%	0.112%
5/4/2021	Victory Capital Management Inc.	2,868,858	$20.51M	0.0%	+28.1%	9.879%
4/29/2021	Vigilare Wealth Management	18,000	$0.13M	0.1%	-32.3%	0.062%
2/25/2021	Hsbc Holdings PLC	16,944	$94K	0.0%	N/A	0.068%
2/24/2021	Virtu Financial LLC	18,247	$98K	0.0%	N/A	0.074%
2/17/2021	Jane Street Group LLC	21,230	$0.11M	0.0%	N/A	0.086%
2/16/2021	Squarepoint Ops LLC	20,235	$0.11M	0.0%	N/A	0.082%
2/11/2021	Northern Trust Corp	23,827	$0.13M	0.0%	+82.2%	0.096%
2/10/2021	Renaissance Technologies LLC	41,509	$0.22M	0.0%	-61.3%	0.168%
2/9/2021	Bank of New York Mellon Corp	15,261	$82K	0.0%	N/A	0.062%
2/5/2021	BlackRock Inc.	69,153	$0.37M	0.0%	+221.1%	0.280%

Data available starting January 2016

See Full Table

Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a first-in-class monoclonal antibody that targets the immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase I clinical trial for the treatment of ulcerative colitis; and Phase I clinical trial for the treatment of lupus nephritis. It also develops EQ101 completed phase 1/2 for treatment of cutaneous T cell lymphoma and alopecia areata; and EQ302 to treat gastrointestinal indications. In addition, it serves dermatology, gastroenterology, rheumatology, hematology, transplant science, oncology, and pulmonology area. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.

Today's Range

Now: $0.39

$0.36

$0.41

50 Day Range

MA: $0.76

$0.41

$0.94

52 Week Range

Now: $0.39

$0.37

$2.43

Volume

133,577 shs

Average Volume

360,244 shs

Market Capitalization

$13.90 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.87

Who are the company insiders with the largest holdings of Equillium?: Equillium's top insider shareholders include:
Christine Zedelmayer (COO)
Jason A Keyes (CFO)
Penny Tom (Insider)
Learn More about top insider investors at Equillium.
Who are the major institutional investors of Equillium?: Equillium's top institutional shareholders include:
Takeda Pharmaceutical Co. Ltd. — 5.15%
Renaissance Technologies LLC — 0.74%
DCF Advisers LLC — 0.18%
Concourse Financial Group Securities Inc. — 0.00%
Learn More about top institutional investors of Equillium stock.
Which institutional investors are selling Equillium stock?: Within the previous quarter, EQ stock was sold by these institutional investors:
Renaissance Technologies LLC
During the previous year, company insiders that have sold Equillium company stock include:
Christine Zedelmayer (COO)
Jason A Keyes (CFO)
Penny Tom (Insider)
Learn More investors selling Equillium stock.
Which institutional investors are buying Equillium stock?: Within the last quarter, EQ stock was acquired by institutional investors including:
Takeda Pharmaceutical Co. Ltd.
DCF Advisers LLC